629 related articles for article (PubMed ID: 10580413)
21. Exendin-4 and exercise promotes beta-cell function and mass through IRS2 induction in islets of diabetic rats.
Park S; Hong SM; Sung SR
Life Sci; 2008 Feb; 82(9-10):503-11. PubMed ID: 18237751
[TBL] [Abstract][Full Text] [Related]
22. Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells.
List JF; Habener JF
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E875-81. PubMed ID: 15140754
[TBL] [Abstract][Full Text] [Related]
23. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
24. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
Perry T; Lahiri DK; Chen D; Zhou J; Shaw KT; Egan JM; Greig NH
J Pharmacol Exp Ther; 2002 Mar; 300(3):958-66. PubMed ID: 11861804
[TBL] [Abstract][Full Text] [Related]
25. The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms.
Lotfy M; Singh J; Rashed H; Tariq S; Zilahi E; Adeghate E
Cell Tissue Res; 2014 Nov; 358(2):343-58. PubMed ID: 25115772
[TBL] [Abstract][Full Text] [Related]
26. Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells.
Movassat J; Beattie GM; Lopez AD; Hayek A
J Clin Endocrinol Metab; 2002 Oct; 87(10):4775-81. PubMed ID: 12364473
[TBL] [Abstract][Full Text] [Related]
27. Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: a strategy for production of pancreatic beta-cell lines for use in transplantation.
Chepurny OG; Holz GG
Cell Tissue Res; 2002 Feb; 307(2):191-201. PubMed ID: 11845326
[TBL] [Abstract][Full Text] [Related]
28. Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.
Malendowicz LK; Macchi C; Nussdorfer GG; Nowak KW; Zyterska A; Ziolkowska A
Int J Mol Med; 2003 Jun; 11(6):763-6. PubMed ID: 12736719
[TBL] [Abstract][Full Text] [Related]
29. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
Holz GG; Chepurny OG
Curr Med Chem; 2003 Nov; 10(22):2471-83. PubMed ID: 14529486
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of impaired glucose-potentiated insulin secretion in diabetic 90% pancreatectomy rats. Study using glucagonlike peptide-1 (7-37).
Hosokawa YA; Hosokawa H; Chen C; Leahy JL
J Clin Invest; 1996 Jan; 97(1):180-6. PubMed ID: 8550831
[TBL] [Abstract][Full Text] [Related]
32. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
[TBL] [Abstract][Full Text] [Related]
33. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
Kodera R; Shikata K; Kataoka HU; Takatsuka T; Miyamoto S; Sasaki M; Kajitani N; Nishishita S; Sarai K; Hirota D; Sato C; Ogawa D; Makino H
Diabetologia; 2011 Apr; 54(4):965-78. PubMed ID: 21253697
[TBL] [Abstract][Full Text] [Related]
34. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
Baron AD; Kim D; Weyer C
Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
[TBL] [Abstract][Full Text] [Related]
35. Bioactive GLP-1 in gut, receptor expression in pancreas, and insulin response to GLP-1 in diabetes-prone rats.
Valverde I; Wang GS; Burghardt K; Kauri LM; Redondo A; Acitores A; Villanueva-Peñacarrillo ML; Courtois P; Sener A; Cancelas J; Malaisse WJ; Scott FW
Endocrine; 2004 Feb; 23(1):77-84. PubMed ID: 15034199
[TBL] [Abstract][Full Text] [Related]
36. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Cho JM; Jang HW; Cheon H; Jeong YT; Kim DH; Lim YM; Choi SH; Yang EK; Shin CY; Son MH; Kim SH; Kim HJ; Lee MS
Diabetes Res Clin Pract; 2011 Jan; 91(1):72-9. PubMed ID: 21093089
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of action of glucagon-like peptide 1 in the pancreas.
Doyle ME; Egan JM
Pharmacol Ther; 2007 Mar; 113(3):546-93. PubMed ID: 17306374
[TBL] [Abstract][Full Text] [Related]
38. Glucagon-like peptide-1 enhances production of insulin in insulin-producing cells derived from mouse embryonic stem cells.
Bai L; Meredith G; Tuch BE
J Endocrinol; 2005 Aug; 186(2):343-52. PubMed ID: 16079260
[TBL] [Abstract][Full Text] [Related]
39. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy.
Kan M; Guo G; Singh B; Singh V; Zochodne DW
J Neuropathol Exp Neurol; 2012 Jun; 71(6):494-510. PubMed ID: 22588388
[TBL] [Abstract][Full Text] [Related]
40. Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity.
Ghanaat-Pour H; Sjöholm A
Diabetes Metab Res Rev; 2009 Feb; 25(2):163-84. PubMed ID: 19065603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
